Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
87%
Overall Survival
85%
Chimeric Antigen Receptor T-cell Therapy
67%
Point-of-care
59%
Positron Emission Tomography-computed Tomography (PET-CT)
54%
Rituximab
54%
Progression-free Survival
54%
Anti-CD19 chimeric Antigen Receptor T Cells
53%
Follicular Lymphoma
51%
Relapsed or Refractory
49%
Chimeric Antigen Receptor T Cells (CAR-T)
48%
FDG PET-CT
46%
Graft-versus-host Disease (GvHD)
46%
Complete Remission
44%
Large B-cell Lymphoma
43%
Bendamustine
43%
Oncology Patients
39%
Fluorine-18
39%
Israeli
39%
Fluorodeoxyglucose
39%
Immunoglobulin Genes
39%
Aggressive B-cell Lymphoma
39%
Complete Response
36%
Lymphoma Patients
35%
Cyclophosphamide
34%
Retrospective Analysis
33%
Hematological Malignancies
33%
Overall Response Rate
32%
Salvage Therapy
31%
Disease Progression
31%
Confidence Interval
31%
High Risk
29%
Genotype
29%
Hodgkin Lymphoma
28%
Adult Patients
27%
Treatment Failure
26%
Malignancy
26%
Transplant Eligibility
26%
POD24
24%
Polymorphism
24%
COVID-19
24%
Clinical Outcomes
24%
Lineage Tree
23%
Leukemia Patients
23%
Clinical Characteristics
23%
B Cells
23%
Complementarity-determining Region 3 (CDR3)
21%
Tree-based Analysis
21%
Transplantation
20%
Allogeneic Transplantation
19%
Medicine and Dentistry
Overall Survival
100%
Positron Emission Tomography-Computed Tomography
99%
B Cell
72%
Large-Cell Lymphoma
69%
Progression Free Survival
64%
Non-Hodgkin Lymphoma
63%
Chimeric Antigen Receptor T-Cell Immunotherapy
59%
Hodgkin's Lymphoma
59%
Diseases
58%
Follicular Lymphoma
57%
Rituximab
54%
Chimeric Antigen Receptor T-Cell
46%
Salvage Therapy
43%
Fluorine-18
39%
Deoxyglucose
39%
Cyclophosphamide
34%
Polyethylene Terephthalate
34%
Bendamustine
29%
T Cell
24%
COVID-19
23%
Adriamycin Bleomycin Vinblastine Dacarbazine
23%
B-Cell Lymphoma
19%
Allogeneic Stem Cell Transplantation
19%
Multiple Myeloma
19%
Cyclosporine
19%
Graft Versus Host Reaction
19%
COVID-19 Vaccine
19%
Cardiovascular Effect
19%
Humoral Immunity
19%
Quality of Life
19%
Meta-Analysis
19%
Bortezomib
19%
Gemcitabine
19%
Cancer
19%
BEACOPP
19%
Lymph Duct
19%
Chimeric Antigen Receptor T-Cell Therapy
19%
Conditioning
19%
Lidocaine
19%
Acute Lymphoblastic Leukemia
19%
Fludarabine
19%
Cell Transplantation
19%
Brentuximab Vedotin
19%
Thalidomide
19%
Chronic Lymphocytic Leukemia
19%
Precursor
19%
Messenger RNA
19%
Ethnic Difference
19%
Odds Ratio
19%
Dexamethasone
19%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
89%
Diseases
66%
Nonhodgkin Lymphoma
62%
Follicular Lymphoma
60%
Hodgkin Disease
59%
Chimeric Antigen Receptor
59%
Polyethylene Terephthalate
54%
Progression Free Survival
46%
Bendamustine
43%
B Cell Lymphoma
39%
Remission
36%
Cyclophosphamide
34%
Rituximab
34%
Infection
32%
Chemotherapy
25%
Large Cell Lymphoma
23%
Actin
19%
COVID-19 Vaccine
19%
Fludarabine
19%
Graft Versus Host Reaction
19%
Acute Lymphoblastic Leukemia
19%
Bortezomib
19%
Ciclosporin
19%
Thalidomide
19%
Hematopoietic System Malignancy
19%
Lenalidomide
19%
Case-Control Study
19%
Syndrome
19%
Brentuximab Vedotin
19%
Dexamethasone
19%
Multiple Myeloma
19%
Articaine
19%
Nucleation
19%
Local Anesthetic Agent
19%
Gemcitabine
19%
Leukemia
19%
Lidocaine
19%
Fluorine 18
19%
Deoxyglucose
19%
Mantle Cell Lymphoma
19%
Ibrutinib
19%
Myelodysplastic Syndrome
19%
Messenger RNA
19%
Prednisone
14%
Vincristine Sulfate
14%
Recurrent Disease
13%
Malignant Neoplasm
12%
Adverse Event
10%
Disease Exacerbation
10%
Disease Free Survival
9%